المؤلفون: Herranz, Marta, Buenestado-Serrano, Sergio, Martín-Escolano, Javier, Molero-Salinas, Andrea, Alonso, Roberto, Catalán, Pilar, Muñoz, Patricia, García de Viedma, Darío, Pérez-Lago, Laura, Alcalá, Luis, Aldámiz, Teresa, Álvarez, Beatriz, Álvarez-Uría, Ana, Arias, Alexi, Bermúdez, Elena, Bouza, Emilio, Burillo, Almudena, Carrillo, Raquel, Cercenado, Emilia, Cobos, Alejandro, Díez, Cristina, Escribano, Pilar, Estévez, Agustín, Fanciulli, Chiara, Galar, Alicia, García, M Dolores, Gijón, Paloma, González, Adolfo, Guillén, Helmuth, Guinea, Jesús, Irigoyen, Álvaro, Haces, Laura Vanessa, Kestler, Martha, López, Juan Carlos, Losada, Carmen Narcisa, Machado, Marina, Marín, Mercedes, Martín-Rabadán, Pablo, Montilla, Pedro, Olmedo, María, Padilla, Belén, Palomo, María, Pérez-Granda, María Jesús, Pérez, Leire, Reigadas, Elena

المساهمون: Piantadosi, Anne, MEC | Instituto de Salud Carlos III, EC | European Regional Development Fund, CIBER-Consorcio Centro de Investigación Biomédica en Red, Instituto de Investigación sanitaria Gregorio Marañón

المصدر: Microbiology Spectrum ; volume 11, issue 5 ; ISSN 2165-0497

الوصف: During the COVID-19 pandemic, several SARS-CoV-2 variants of concern (VOCs) of particular relevance emerged. Early detection of VOCs entering a country is essential to control spread. The alert triggered by the first suspected case of the Omicron variant in Spain in a traveler arriving from South Africa in November 2021 provided a unique opportunity to evaluate four different methodological strategies tailored to rapid identification of Omicron. The different approaches were designed to respond to the different technical resources available in different settings. First, we used melting probes in RT-PCR to determine the presence of four Omicron signatures (K417N, E484A, P681H, and absence of L452R): three probes showed deviations in temperature (Tm) values relative to the reference codons (E484K-15.8°C, P681H-5.2°C, and L452R-7.2°C) and one maintained the reference value (K417N). The deviation in Tm of P681H suggested the presence of the characteristic Omicron N679K mutation in the probe hybridization region; these data pointed to the presence of Omicron alleles. Second, the presence of 29 of the 33 characteristic single nucleotide polymorphisms (SNPs) in the Omicron variant S-gene was identified by Sanger sequencing of nine amplicons. The final two strategies involved identification of 47 of the 50 non-synonymous and indel mutations attributed to Omicron by rapid nanopore whole genome sequencing (WGS) and by Illumina WGS technology. These strategies enabled us to pre-assign the first Omicron case in Spain with high certainty 2 h after receipt of RNA and to confirm it genomically 3 h later, so that the Public Health authorities could be rapidly notified. IMPORTANCE The study presents different experimental alternatives to identify new variants of concern (VOCs) of SARS-CoV-2 entering a certain population. Early detection of a new VOC is crucial for surveillance and control of spread. The objective is to provide laboratories with tools adapted to their resource capabilities that offer a sufficient level ...

الإتاحة: https://doi.org/10.1128/spectrum.01075-23Test

المؤلفون: Tejerina, Francisco, Catalan, Pilar, Rodriguez-Grande, Cristina, Adan, Javier, Rodriguez-Gonzalez, Carmen, Muñoz, Patricia, Aldamiz, Teresa, Diez, Cristina, Perez, Leire, Fanciulli, Chiara, Garcia de Viedma, Dario, Alcalá, Luis, Alonso, Roberto, Álvarez, Beatriz, Álvarez-Uría, Ana, Arias, Alexi, Arroyo, Luis Antonio, Berenguer, Juan, Bermúdez, Elena, Bouza, Emilio, Burillo, Almudena, Candela, Ana, Carrillo, Raquel, Cercenado, Emilia, Cobos, Alejandro, Escribano, Pilar, Estévez, Agustín, Fernandez, Silvia, Galar, Alicia, García, Mª Dolores, Gijón, Paloma, González, Adolfo, Guillén, Helmuth, Guinea, Jesús, Haces, Laura Vanessa, Kestler, Martha, López, Juan Carlos, Losada, Carmen Narcisa, Machado, Marina, Marín, Mercedes, Martín, Pablo, Martín, Paloma, Montilla, Pedro, Moure, Zaira, Olmedo, María, Padilla, Belén, Palomo, María, Parras, Francisco, Pérez-Granda, María Jesús

المصدر: BMC Infectious Diseases ; volume 22, issue 1 ; ISSN 1471-2334

مصطلحات موضوعية: Infectious Diseases

الوصف: Background There is a paucity of knowledge on the long-term outcome in patients diagnosed with COVID-19. We describe a cohort of patients with a constellation of symptoms occurring four weeks after diagnosis causing different degrees of reduced functional capacity. Although different hypothesis have been proposed to explain this condition like persistent immune activation or immunological dysfunction, to date, no physiopathological mechanism has been identified. Consequently, there are no therapeutic options besides symptomatic treatment and rehabilitation. Methods We evaluated patients with symptoms that persisted for at least 4 weeks after COVID-19. Epidemiological and clinical data were collected. Blood tests, including inflammatory markers, were conducted, and imaging studies made if deemed necessary. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription polymerase chain reaction (RT-PCR) in plasma, stool, and urine were performed. Patients were offered antiviral treatment (compassionate use). Results We evaluated 29 patients who reported fatigue, muscle pain, dyspnea, inappropriate tachycardia, and low-grade fever. Median number of days from COVID-19 to positive RT-PCR in extra-respiratory samples was 55 (39–67). Previous COVID-19 was mild in 55% of the cases. Thirteen patients (45%) had positive plasma RT-PCR results and 51% were positive in at least one RT-PCR sample (plasma, urine, or stool). Functional status was severely reduced in 48% of the subjects. Eighteen patients (62%) received antiviral treatment. Improvement was seen in most patients (p = 0.000) and patients in the treatment group achieved better outcomes with significant differences (p = 0.01). Conclusions In a cohort of COVID-19 patients with persistent symptoms, 45% of them have detectable plasma SARS-CoV-2 RNA. Our results indicate possible systemic viral persistence in these patients, who may benefit of antiviral treatment strategies.

الإتاحة: https://doi.org/10.1186/s12879-022-07153-4Test

المؤلفون: Pérez-Lago, Laura, Machado, Marina, Herranz, Marta, Sola-Campoy, Pedro J, Suárez-González, Julia, Martínez-Laperche, Carolina, Comas, Iñaki, Alcalá, Luis, Catalán, Pilar, Muñoz, Patricia, García de Viedma, Darío, Adán-Jiménez, Javier, Aldámiz, Teresa, Alonso, Roberto, Álvarez, Beatriz, Álvarez-Uría, Ana, Arias, Alexi, Arroyo, Luis Antonio, Berenguer, Juan, Bermúdez, Elena, Bouza, Emilio, Burillo, Almudena, Candela, Ana, Carrillo, Raquel, Cercenado, Emilia, Cobos, Alejandro, Díez, Cristina, Escribano, Pilar, Estévez, Agustín, Fanciulli, Chiara, Galar, Alicia, García, Mª Dolores, Gijón, Paloma, González, Adolfo, Guillén, Helmuth, Guinea, Jesús, Haces, Laura Vanessa, Kestler, Martha, López, Juan Carlos, Losada, Carmen Narcisa, Marín, Mercedes, Martín, Pablo, Montilla, Pedro, Moure, Zaira

المساهمون: Instituto de Salud Carlos III, Consejo Superior de Investigaciones Científicas, Miguel Servet Contract

المصدر: Open Forum Infectious Diseases ; volume 8, issue 9 ; ISSN 2328-8957

مصطلحات موضوعية: Infectious Diseases, Oncology

الإتاحة: https://doi.org/10.1093/ofid/ofab402Test
http://academic.oup.com/ofid/article-pdf/8/9/ofab402/40423749/ofab402.pdfTest

المؤلفون: Machado, Marina, Valerio, Maricela, Álvarez‐Uría, Ana, Olmedo, María, Veintimilla, Cristina, Padilla, Belén, De la Villa, Sofía, Guinea, Jesús, Escribano, Pilar, Ruiz‐Serrano, María Jesús, Reigadas, Elena, Alonso, Roberto, Guerrero, José Eugenio, Hortal, Javier, Bouza, Emilio, Muñoz, Patricia, Alcalá, Luis, Aldámiz, Teresa, Álvarez, Beatriz, Arias, Alexi, Arroyo, Luis Antonio, Bermúdez, Elena, Burillo, Almudena, Candela, Ana, Carrillo, Raquel, Catalán, Pilar, Cercenado, Emilia, Cobos, Alejandro, Díez, Cristina, Estévez, Agustín, Fanciulli, Chiara, Galar, Alicia, García, Mª Dolores, Viedma, Darío García, Gijón, Paloma, González, Adolfo, Guillén, Helmuth, Haces, Laura Vanessa, Kestler, Martha, López, Juan Carlos, Losada, Carmen Narcisa, Marín, Mercedes, Martín, Pablo, Montilla, Pedro, Moure, Zaira, Palomo, María, Parras, Francisco, Pérez‐Granda, María Jesús, Pérez, Laura, Pérez, Leire, Pescador, Paula, Rincón, Cristina, Rodríguez, Belén, Rodríguez, Sara, Rojas, Adriana, Sánchez, Carlos, Sánchez, Mar, Serrano, Julia, Tejerina, Francisco, Vesperinas, Lara, Vicente, Teresa

المصدر: Mycoses

مصطلحات موضوعية: 0301 basic medicine, ARDS, medicine.medical_specialty, medicine.medical_treatment, 030106 microbiology, Review Article, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, Galactomannan, chemistry.chemical_compound, 0302 clinical medicine, Tocilizumab, COVID‐19, fungal diseases, Intensive care, Internal medicine, medicine, Humans, Prospective Studies, Prospective cohort study, Review Articles, intensive care, Mechanical ventilation, Invasive Pulmonary Aspergillosis, medicine.diagnostic_test, business.industry, SARS-CoV-2, Aspergillus fumigatus, COVID-19, General Medicine, medicine.disease, SARS‐CoV‐2 infection, antifungal therapy, Bronchoalveolar lavage, Infectious Diseases, chemistry, Aspergillus infection, fungal infections, Complication, business

الوصف: Objectives Information on the recently COVID‐19‐associated pulmonary aspergillosis (CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU patients with coronavirus disease 2019 (COVID‐19), and review the published literature from Western countries. Methods Prospective study (March to May, 2020) that included all COVID‐19 patients admitted to a tertiary hospital. Modified AspICU and European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria were used. Results COVID‐19‐associated pulmonary aspergillosis was diagnosed in eight patients (3.3% of 239 ICU patients), mostly affected non‐immunocompromised patients (75%) with severe acute respiratory distress syndrome (ARDS) receiving corticosteroids. Diagnosis was established after a median of 15 days under mechanical ventilation. Bronchoalveolar lavage was performed in two patients with positive Aspergillus fumigatus cultures and galactomannan (GM) index. Serum GM was positive in 4/8 (50%). Thoracic CT scan findings fulfilled EORTC/MSG criteria in one case. Isavuconazole was used in 4/8 cases. CAPA‐related mortality was 100% (8/8). Compared with colonised patients, CAPA subjects were administered tocilizumab more often (100% vs. 40%, p = .04), underwent longer courses of antibacterial therapy (13 vs. 5 days, p = .008), and had a higher all‐cause mortality (100% vs. 40%, p = .04). We reviewed 96 similar cases from recent publications: 59 probable CAPA (also putative according modified AspICU), 56 putative cases and 13 colonisations according AspICU algorithm; according EORTC/MSG six proven and two probable. Overall, mortality in the reviewed series was 56.3%. Conclusions COVID‐19‐associated pulmonary aspergillosis must be considered a serious and potentially life‐threatening complication in patients with severe COVID‐19 receiving immunosuppressive treatment.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a5d289155044518c1bf28b191f43cfTest